BRPI0007481A - formulação contendo cepa de bifidobacterium e uso da mesma - Google Patents

formulação contendo cepa de bifidobacterium e uso da mesma

Info

Publication number
BRPI0007481A
BRPI0007481A BRPI0007481A BRPI0007481A BRPI0007481A BR PI0007481 A BRPI0007481 A BR PI0007481A BR PI0007481 A BRPI0007481 A BR PI0007481A BR PI0007481 A BRPI0007481 A BR PI0007481A BR PI0007481 A BRPI0007481 A BR PI0007481A
Authority
BR
Brazil
Prior art keywords
strain
bifidobacterium
inflammatory activity
formulation containing
inflammatory
Prior art date
Application number
BRPI0007481A
Other languages
English (en)
Inventor
John Kevin Collins
Gerald Christopher O'sullivan
Liam O'mahony
Fergus Shanahan
Original Assignee
Entpr Ie Trd As Bioresearch Ie
Univ College Cork Nat Univ Ie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE990033A external-priority patent/IE990033A1/en
Application filed by Entpr Ie Trd As Bioresearch Ie, Univ College Cork Nat Univ Ie filed Critical Entpr Ie Trd As Bioresearch Ie
Publication of BRPI0007481A publication Critical patent/BRPI0007481A/pt
Publication of BRPI0007481B1 publication Critical patent/BRPI0007481B1/pt
Publication of BRPI0007481B8 publication Critical patent/BRPI0007481B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/179—Sakei
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"cepa de bifidobacterium, agente antimicrobiano e formulação obtidos da cepa de bifidobacterium". uma cepa de bifidobacterium isolada do trato gastrintestinal humano ressecado e lavado é significativamente imunomoduladora seguindo consumo em humanos. a cepa é útil na profilaxia e/ou tratamento de atividade inflamatória indesejável, especialmente atividade inflamatória gastrintestinal tal como doença inflamatória do intestino ou síndrome do intestino irritável. a atividade inflamatória também pode ser causada por câncer.
BRPI0007481 1999-01-15 2000-01-17 formulação contendo cepa de bifidobacterium e uso da mesma BRPI0007481B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE990033A IE990033A1 (en) 1999-01-15 1999-01-15 Bifidobacterium longum infantis in the treatment of inflammatory bowel disease
IE990782 1999-09-20
PCT/IE2000/000008 WO2000042168A2 (en) 1999-01-15 2000-01-17 Bifidobacterium in the treatment of inflammatory disease

Publications (3)

Publication Number Publication Date
BRPI0007481A true BRPI0007481A (pt) 2002-04-09
BRPI0007481B1 BRPI0007481B1 (pt) 2015-12-15
BRPI0007481B8 BRPI0007481B8 (pt) 2021-07-06

Family

ID=26320235

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0007550-7A BR0007550A (pt) 1999-01-15 2000-01-17 Uso de cepas de lactobacillus salivarius
BRPI0007481 BRPI0007481B8 (pt) 1999-01-15 2000-01-17 formulação contendo cepa de bifidobacterium e uso da mesma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0007550-7A BR0007550A (pt) 1999-01-15 2000-01-17 Uso de cepas de lactobacillus salivarius

Country Status (22)

Country Link
US (13) US20020006432A1 (pt)
EP (4) EP1143985B1 (pt)
JP (2) JP2004502633A (pt)
CN (3) CN100552016C (pt)
AT (3) ATE367820T1 (pt)
AU (3) AU3071700A (pt)
BR (2) BR0007550A (pt)
CA (3) CA2359334C (pt)
DE (3) DE60035670T2 (pt)
DK (2) DK1143985T3 (pt)
ES (2) ES2290008T3 (pt)
HK (1) HK1044964B (pt)
ID (2) ID29150A (pt)
IE (1) IE20000033A1 (pt)
IL (3) IL144185A0 (pt)
MX (2) MXPA01007152A (pt)
NO (2) NO327792B1 (pt)
NZ (2) NZ529353A (pt)
PT (1) PT1141235E (pt)
RU (2) RU2308483C2 (pt)
TR (2) TR200102058T2 (pt)
WO (3) WO2000042168A2 (pt)

Families Citing this family (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US7029702B2 (en) * 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
WO2001010448A1 (en) * 1999-08-09 2001-02-15 University Of Maryland, Baltimore Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids
WO2002002138A1 (en) * 2000-07-03 2002-01-10 Probendo Pty Ltd Treating endotoxemia and related disorders with probiotics
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20020054865A1 (en) * 2000-09-21 2002-05-09 Minoru Fujimori Anaerobic bacterium as a drug for cancer gene therapy
ATE490776T1 (de) 2000-10-06 2010-12-15 Nestec Sa Verwendung von probiotischen milchsäure- produzierende bakterien zur zum schutz der haut gegen uv-induzierter allergischen reaktionen und entzündungskrankheiten oder immunsuppression
IT1320772B1 (it) * 2000-11-02 2003-12-10 Proge Farm Srl Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale
US7510735B2 (en) * 2001-02-01 2009-03-31 Kabushiki Kaisha Yakult Honsha Method of evaluating the extent of reaching the intestine of bifidobacterium in fermented milk food or drink
AU2002249531A1 (en) * 2001-04-02 2002-10-28 Alimentary Health Limited Immunotherapy based on dendritic cells
JP4671384B2 (ja) * 2001-05-15 2011-04-13 雪印乳業株式会社 新規乳酸菌株
EP1264893A1 (en) 2001-06-08 2002-12-11 Teagasc Dairy Products Research Centre CLA biosynthesis by bifidobacteria
PE20030274A1 (es) * 2001-07-26 2003-05-08 Alimentary Health Ltd Cepas de lactobacillus salivarius
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
JP5116194B2 (ja) * 2001-09-04 2013-01-09 株式会社ヤクルト本社 炎症性腸疾患予防治療剤
WO2003022255A2 (en) * 2001-09-05 2003-03-20 Vsl Pharmaceuticals, Inc. Lactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
EP1449915B1 (en) * 2001-12-07 2006-04-05 Morinaga Milk Industry Co., Ltd. Bifidobacterium longum
US6941649B2 (en) * 2002-02-05 2005-09-13 Force10 Networks, Inc. Method of fabricating a high-layer-count backplane
DE10206995B4 (de) * 2002-02-19 2014-01-02 Orthomol Pharmazeutische Vertriebs Gmbh Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
EP1511502A2 (en) * 2002-06-13 2005-03-09 Alimentary Health Limited Probiotic therapies using lactobacillus reuteri
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
US7740838B2 (en) * 2002-12-05 2010-06-22 Danisco A/S Bacterial composition and its use
FR2848115B1 (fr) * 2002-12-05 2005-03-25 Rhodia Chimie Sa Composition de bacteries et son utilisation
JP2004189672A (ja) * 2002-12-11 2004-07-08 Gen Corp:Kk 抗下痢症組成物
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
SE526711C2 (sv) * 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8192733B2 (en) * 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
GB0323039D0 (en) * 2003-10-01 2003-11-05 Danisco Method
CN101001635A (zh) * 2003-12-04 2007-07-18 生物膜策略公司 预防生物膜形成、减少现有生物膜和减少细菌群的方法和组合物
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
WO2005072718A1 (ja) * 2004-01-28 2005-08-11 Kurume University 乳清発酵物を含有する医薬組成物
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
WO2006012536A2 (en) * 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
KR100568036B1 (ko) 2004-08-12 2006-04-07 하남주 장기능 활성화 및 면역기능 강화작용을 하는비피도박테리움 균주 및 이를 함유하는 생균제제
JP2006166829A (ja) * 2004-12-17 2006-06-29 Best Ecology:Kk アイスサプリメント及びその製造方法
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
AU2011205121B2 (en) * 2005-04-08 2012-07-05 Alimentary Health Ltd Method of use of orally administered probiotic bifidobacteria for human beauty benefits
AU2006235307B2 (en) 2005-04-08 2011-07-14 Alimentary Health Ltd Methods of use of orally administered probiotic Bifidobacteria for human beauty benefits
US20060228448A1 (en) 2005-04-11 2006-10-12 The Iams Company Pet food compositions comprising two components
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
ATE512211T1 (de) 2005-05-31 2011-06-15 Iams Company Feline probiotische lactobacilli
CN101374425A (zh) * 2005-07-20 2009-02-25 荷兰联合利华有限公司 含有有益细菌的可食用产品
ITMI20051510A1 (it) * 2005-08-02 2007-02-03 Proge Farm Srl Uso di specifici batteri lattici per la preparazione di composizioni iunomodulanti
RU2297835C1 (ru) * 2005-09-26 2007-04-27 Закрытое акционерное общество "Партнер" Препарат для лечения неинфекционных воспалительных болезней кишечника
US8246946B2 (en) * 2005-09-27 2012-08-21 Cobb & Associates Treatment of bipolar disorder utilizing anti-fungal compositions
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
EP2002842B1 (en) * 2006-03-31 2012-04-11 Morinaga Milk Industry Co., Ltd. Method for production of the interleukin production regulator
WO2007133188A1 (en) * 2006-05-01 2007-11-22 Cobb & Company, Llp Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2008053444A2 (en) 2006-11-01 2008-05-08 The Procter & Gamble Company Treating a respiratory condition with bifidobacterium
US7964238B2 (en) * 2007-01-29 2011-06-21 Guardian Industries Corp. Method of making coated article including ion beam treatment of metal oxide protective film
EP2124966B1 (en) 2007-02-01 2015-09-09 IAMS Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
AU2007347318A1 (en) * 2007-02-22 2008-08-28 Jurgen Schrezenmeir Probiotic, gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in humans
WO2008106373A1 (en) * 2007-02-28 2008-09-04 Mead Johnson Nutrition Company Product containing inactivated probiotic for children or infants
MX2009010187A (es) * 2007-03-27 2009-10-19 Procter & Gamble Metodos y estuches para administracion de probioticos.
BRPI0809448A2 (pt) * 2007-03-28 2014-09-09 Alimentary Health Ltd Cepas de bifidobacterium probióticas
CA2682242A1 (en) * 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic bifidobacterium longum strain
WO2008135959A1 (en) * 2007-05-04 2008-11-13 Alimentary Health Limited An exopolysaccharide
EP2522358B1 (en) 2007-06-27 2016-11-09 Laboratorios Ordesa, S.l. Peptides against rotavirus infection
JP2009057346A (ja) * 2007-09-03 2009-03-19 Kirin Holdings Co Ltd 免疫バランス調節用組成物
FR2921795B1 (fr) * 2007-10-03 2011-04-29 Gervais Danone Sa Utilisation d'une souche de bifidobacterium,pour la preparation d'une composition destinee a la prevention et/ou au traitement de manifestations de type allergique
JP2011504366A (ja) * 2007-11-26 2011-02-10 プラント バイオサイエンス リミティド エンドリシン活性を有する新規ポリペプチド及びその使用
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
ES2395838T3 (es) * 2007-12-21 2013-02-15 Compagnie Gervais Danone Método para disminuir el contorno abdominal administrando una bacteria del tipo Bifidobacterium
ES2343499B1 (es) * 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
RU2375960C2 (ru) * 2008-01-28 2009-12-20 Федеральное государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФГУН МНИИЭМ им. Г.Н. Габрического Роспотребнадзора) Способ определения ареактогенного действия препарата пробиотика
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US20110189148A1 (en) * 2008-06-25 2011-08-04 Ritter Pharmaceuticals, Inc. Lactose compositions with decreased lactose content
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
CN102089422B (zh) * 2008-07-11 2013-07-17 科.汉森有限公司 新的益生长双歧杆菌
RU2453320C2 (ru) * 2008-08-05 2012-06-20 Виктор Владимирович Чалов Композиция для перорального применения, содержащая непатогенные микроорганизмы, обладающая способностью нормализовать микрофлору кишечника (варианты)
CA2735659C (en) * 2008-09-11 2013-10-29 The Iams Company Animal feed kibble with protein-based core and related methods
US20100074870A1 (en) * 2008-09-19 2010-03-25 Bristol-Myers Squibb Company Probiotic infant products
KR101057357B1 (ko) 2008-09-22 2011-08-17 광주과학기술원 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
MX356598B (es) * 2008-11-11 2018-06-04 Alimentary Health Ltd Bifidobacterium longum.
SG173832A1 (en) 2009-02-24 2011-09-29 Ritter Pharmaceuticals Inc Prebiotic formulations and methods of use
GB0908949D0 (en) 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
US20100330151A1 (en) * 2009-06-25 2010-12-30 Mary Elaine Freeland Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US20110027412A1 (en) 2009-07-31 2011-02-03 Kris Eugene Spence Compositions and Methods for Promoting Gastrointestinal and/or Cardiovascular Health
TR201807143T4 (tr) 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
US8765706B2 (en) 2009-09-02 2014-07-01 Kyoto Prefectural Public University Corporation Composition comprising rna derived from lactic acid bacterium as effective component
EP2485744A4 (en) * 2009-10-09 2014-01-22 Prothera Inc COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED
CN107574131A (zh) * 2009-11-11 2018-01-12 营养健康有限公司 益生菌双歧杆菌菌株
ES2610829T3 (es) * 2009-11-11 2017-05-03 Alimentary Health Limited Cepa de Bifidobacterium
ES2437940T3 (es) 2010-01-28 2014-01-15 Ab-Biotics S.A. Composición probiótica para uso en el tratamiento de la inflamación del intestino
ES2730828T3 (es) 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
JP5852558B2 (ja) * 2010-03-26 2016-02-03 株式会社明治 腸管免疫の抑制剤のスクリーニング方法
RU2434058C1 (ru) * 2010-04-26 2011-11-20 Татьяна Александровна Левченко Штамм bifidobacterium longum, используемый для получения бифидосодержащей продукции
RU2451741C2 (ru) * 2010-04-26 2012-05-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum АБД-3, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2451740C2 (ru) * 2010-04-26 2012-05-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum АБД-7, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
EP2563372A4 (en) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc PREBIOTIC FORMULATIONS AND METHODS OF USE
RU2427636C1 (ru) * 2010-05-14 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2427626C1 (ru) * 2010-05-14 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2427628C1 (ru) * 2010-05-28 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2427629C1 (ru) * 2010-05-28 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
RU2427630C1 (ru) * 2010-05-28 2011-08-27 Татьяна Александровна Левченко ШТАММ Bifidobacterium longum, ИСПОЛЬЗУЕМЫЙ ДЛЯ ПОЛУЧЕНИЯ БИФИДОСОДЕРЖАЩЕЙ ПРОДУКЦИИ
WO2011148219A1 (en) * 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving the enteric nervous system
CN102269858A (zh) 2010-06-02 2011-12-07 北京智朗芯光科技有限公司 自动聚焦系统和自动聚焦方法
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
FR2962045B1 (fr) * 2010-07-05 2012-08-17 Bifinove Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
PH12013500224A1 (en) 2010-08-04 2013-04-08 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
CN103209596A (zh) * 2010-11-11 2013-07-17 雀巢产品技术援助有限公司 含有益生微生物的冷冻糖食
PL2481299T3 (pl) 2011-01-31 2017-09-29 Synformulas Gmbh Szczepy bifidobacterium bifidum do stosowania w chorobach przewodu pokarmowego
MX2013010343A (es) 2011-03-09 2014-04-30 Univ Minnesota Composicion y metodos para el transplante de microbiota de colon.
WO2012140636A1 (en) 2011-04-11 2012-10-18 Alimentary Health Limited A probiotic formulation
RU2460777C1 (ru) * 2011-04-21 2012-09-10 Общество с ограниченной ответственностью "Бифилюкс" Штамм bifidobacterium longum, используемый для получения бифидосодержащей продукции
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
KR101355440B1 (ko) 2011-10-26 2014-02-05 주식회사한국야쿠르트 류마티스 관절염 예방 효능을 갖는 락토바실러스 헬베티쿠스 에이취와이7801 및 이를 유효성분으로 함유하는 제품
CN103131647B (zh) * 2011-11-29 2017-06-27 上海上药信谊药厂有限公司 婴儿双歧杆菌及其制剂
CN116942833A (zh) 2011-12-01 2023-10-27 国立大学法人 东京大学 诱导调节性t细胞的增殖或积累的人源细菌
WO2013099883A1 (ja) * 2011-12-28 2013-07-04 株式会社山田養蜂場本社 IgA産生促進作用を有する新規乳酸菌及びその用途
WO2013107913A1 (en) 2012-01-19 2013-07-25 University College Cork - National University Of Ireland, Cork Gaba-producing culturable bacteria derived from the human gastrointestinal tract
IN2014DN07752A (pt) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
JP6203816B2 (ja) 2012-03-29 2017-09-27 セラバイオーム，エルエルシー 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2925332A4 (en) 2012-08-20 2016-12-21 Boris Markosian PLACENTAL IMP THERAPY AGAINST CANCER
FR2999601B1 (fr) * 2012-12-17 2015-01-30 Urgo Lab Methode pour prevenir et/ou traiter les infections, colonisations ou maladies liees a staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis et/ou bacteroides fragilis
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
KR101434220B1 (ko) * 2013-03-26 2014-08-28 삼육대학교산학협력단 다제내성균에 대한 저해 활성을 갖는 신규 유산균
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
PL3003330T4 (pl) 2013-06-05 2019-03-29 Rebiotix, Inc. Terapia przywracająca mikrobiota (MRT), kompozycje i sposoby wytwarzania
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
JP6637885B2 (ja) 2013-07-21 2020-01-29 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
CN106414709A (zh) 2014-01-24 2017-02-15 宝洁公司 包含微生物的长丝及其制备方法
US20150209469A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Web Comprising a Microorganism-Containing Fibrous Element and Methods for Making Same
US20150209468A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
WO2016102950A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Immune modulation
EP3256004A1 (en) 2015-02-13 2017-12-20 Mars, Incorporated Pet food feeding system
CN107529789A (zh) 2015-04-28 2018-01-02 马斯公司 制备灭菌湿宠物食品的方法
CA2985827A1 (en) 2015-05-14 2016-11-17 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
AU2016268158B2 (en) 2015-05-22 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
BR112017025813A2 (pt) 2015-06-01 2018-08-14 Univ Chicago método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana
US20160354507A1 (en) 2015-06-07 2016-12-08 The Procter & Gamble Company Article of commerce containing absorbent article
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
CN107921072A (zh) 2015-06-09 2018-04-17 雷柏奥提斯有限公司 微生物群恢复治疗（mrt）组合物和制造方法
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
HRP20191949T1 (hr) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
ME03511B (me) 2015-06-15 2020-04-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
US20170020750A1 (en) 2015-07-23 2017-01-26 The Procter & Gamble Company Patch containing microorganism
WO2017032897A1 (en) 2015-08-27 2017-03-02 Alimentary Health Limited Use of bifidobacterium longum and an exopolysaccharide produced thereby
MX2018001820A (es) 2015-08-27 2018-05-17 Procter & Gamble Bifidobacterium longum.
US10537597B2 (en) 2015-10-05 2020-01-21 Schweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In Davos Use of Akkermansia muciniphila for treating inflammatory conditions
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
SG10201913557TA (en) 2016-03-04 2020-02-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
EP3950589A1 (en) * 2016-03-04 2022-02-09 California Institute of Technology New germanosilicate compositions and methods of preparing the same
RU2659240C2 (ru) * 2016-05-23 2018-06-29 федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный университет" (КемГУ) Способ получения функционального продукта питания для реабилитации онкологических больных
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
IT201600121481A1 (it) * 2016-11-30 2018-05-30 Sintal Dietetics Srl L. salivarius sgl03: attività probiotiche e produzione di proteine antimicrobiche
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN107043705A (zh) * 2016-12-30 2017-08-15 大连医科大学 用于建立临床营养菌种资源库的益生菌筛选方法
CN116676222A (zh) * 2017-01-31 2023-09-01 庆熙大学校产学协力团 新型乳酸菌及其用途
EP3589726A1 (en) 2017-02-28 2020-01-08 Alimentary Health Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
ES2877726T3 (es) 2017-05-22 2021-11-17 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
TWI812624B (zh) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
ES2841902T3 (es) 2017-06-14 2021-07-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA51770A (fr) 2017-07-05 2020-05-13 Evelo Biosciences Inc Compositions et méthodes de traitement du cancer à l'aide de bifidobacterium animalis ssp. lactis
WO2019032573A1 (en) * 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
RU2665173C1 (ru) * 2017-09-18 2018-08-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ профилактики атопического дерматита у младенцев путем модуляции микробного механизма гистаминообразования
US20200338144A1 (en) * 2017-11-01 2020-10-29 Biofermin Pharmaceutical Co., Ltd. Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor
KR102024883B1 (ko) 2017-11-24 2019-09-24 주식회사 고바이오랩 락토바실러스 퍼멘텀 kbl 375 균주 및 그 용도
EP3517119B1 (en) 2018-01-26 2021-08-11 Probisearch, S.L.U. Composition comprising new lactobacillus salivarius strain and method for the prevention and treatment of otitis and upper respiratory infections
WO2019145570A1 (en) 2018-01-29 2019-08-01 Alimentary Health Limited A combination product for prophylaxis and treatment of irritable bowel syndrome
JP7285096B2 (ja) * 2018-03-28 2023-06-01 森永乳業株式会社 ストレス緩和用組成物並びに該ストレス緩和用組成物を用いた医薬品組成物及び飲食品組成物
RU2670054C1 (ru) * 2018-04-24 2018-10-17 Федеральное государственное бюджетное учреждение науки Институт клеточного и внутриклеточного симбиоза Уральского отделения Российской академии наук Штамм бактерий Bifidobacterium bifidum ICIS-310 - продуцент ингибитора провоспалительного цитокина INF-γ
SG10202112104UA (en) 2018-05-09 2021-12-30 Ko Biolabs Inc Lactobacillus paracasei strain and use thereof
CN113151036B (zh) * 2018-05-11 2024-08-23 韩国亿诺生物有限公司 具有预防或治疗癌症的效果的新型菌株
AU2019274351B2 (en) 2018-05-23 2022-04-07 Kobiolabs, Inc. Lactobacillus gasseri KBL697 strain and use thereof
CN112236154B (zh) * 2018-05-31 2024-10-18 深圳华大生命科学研究院 一种组合物及其应用
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
CN109486700A (zh) * 2018-08-31 2019-03-19 石家庄君乐宝乳业有限公司 副干酪乳杆菌n1115预防结肠炎的应用及相应的益生菌粉、应用
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
ES2752798B2 (es) * 2018-10-05 2020-08-12 Consejo Superior Investigacion Cepa de Bifidobacterium longum sub. infantis y uso de la misma
KR102074445B1 (ko) 2018-12-12 2020-02-06 주식회사 비피도 류마티스관절염 개선, 예방 또는 치료를 위한 비피도박테리움 롱검 rapo 균주 및 이를 포함하는 조성물
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
US20220273733A1 (en) * 2019-07-26 2022-09-01 Evolve Biosystems, Inc. Nutritive compositions with bioactive proteins
KR102224072B1 (ko) * 2019-08-19 2021-03-10 주식회사 빙그레 면역 조절능력과 혈중콜레스테롤 감소 능력이 모두 뛰어난 비피도박테리엄 롱검 아종 균주 및 이의 용도
CN110547915A (zh) * 2019-08-29 2019-12-10 云南白药清逸堂实业有限公司 应用益生菌的卫生棉制品及其制备方法
CN110452860A (zh) * 2019-09-24 2019-11-15 厦门大学 一种唾液链球菌及其在治疗炎症性肠病药物中的应用
EP4117697A1 (en) 2020-03-13 2023-01-18 PrecisionBiotics Group Limited Bifidobacterium longum
TWI748395B (zh) * 2020-03-31 2021-12-01 豐華生物科技股份有限公司 緩解過敏以及提升運動表現之組合物及其用途
CN113943681B (zh) * 2020-11-12 2023-07-04 江南大学 一株降低炎症反应且具有缓解便秘作用的长双歧杆菌
KR102307603B1 (ko) * 2020-11-13 2021-10-05 주식회사 비피도 비피도박테리움 롱검 rapo (kctc13773bp)를 포함하는 암 예방 또는 치료용 조성물
US12599639B2 (en) * 2021-01-26 2026-04-14 Megmilk Snow Brand Co., Ltd. Joint function-improving composition
CN114317310B (zh) * 2021-03-31 2023-09-22 江苏蓝泽生物科技有限公司 一种抗过敏的婴儿双歧杆菌制剂及其制备方法
CN114558037B (zh) * 2022-02-24 2023-08-15 同济大学 Akk和ls在制备提高认识水平的抗衰老产品中的应用
CN115725456B (zh) * 2022-10-11 2024-06-21 四川大学 一种唾液乳杆菌及其应用
WO2024248549A1 (ko) * 2023-06-01 2024-12-05 재단법인 아산사회복지재단 락토바실러스 살리바리우스 또는 박테로이데스 플레비우스를 포함하는 면역항암제 치료 반응성 및 예후 예측용 바이오마커 및 이를 이용한 면역항암제 치료 반응성 및 예후 예측 방법
CN116574659A (zh) * 2023-06-14 2023-08-11 江南大学 一株可缓解类风湿性关节炎的长双歧杆菌婴儿亚种及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038372B2 (ja) 1975-04-09 1985-08-31 日清製粉株式会社 犬の下痢予防および治療方法
JPS55113718A (en) * 1979-02-27 1980-09-02 Yakult Honsha Co Ltd Antitumor agent
US4435389A (en) * 1980-07-07 1984-03-06 Kabushiki Kaisha Yakult Honsha Composition for promoting growth of bifidobacteria
JPS59118712A (ja) * 1982-12-27 1984-07-09 Morinaga Milk Ind Co Ltd 抗腫瘍剤及びその製造法
US4678773A (en) * 1983-08-26 1987-07-07 Chugai Seiyaku Kabushiki Kaisha Antitumor agent
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
JPH0696538B2 (ja) * 1985-12-19 1994-11-30 株式会社アドバンス 抗発癌剤
SU1817285A1 (ru) * 1986-06-05 1996-08-10 Восточно-Сибирский технологический институт Способ приготовления закваски для производства кисломолочных продуктов
JPS63196521A (ja) * 1987-02-10 1988-08-15 Yakult Honsha Co Ltd 腫瘍細胞障害性因子誘起剤
US5352586A (en) * 1987-05-01 1994-10-04 Biogaia Ab Method of determining the presence of an antibiotic produced by Lactobacillus reuteri
DK686187D0 (da) 1987-12-23 1987-12-23 Hansens Chr Bio Syst Veterinaert praeparat
EP0433299B1 (en) 1988-08-02 1998-05-06 Gastro Services Pty. Limited (ACN 002 994 890) Treatment of gastro-intestinal disorders
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
SE8900546D0 (sv) 1989-02-17 1989-02-17 Bioinvent Int Ab Medel foer inhibering av patogeners adhesion tillvaext och /eller oeverlevnad
NZ244737A (en) 1989-02-21 1993-09-27 Viskase Corp Food packaging polymeric film containing antibiotic material; method of treating foodstuff and food casing therefor
JP2932283B2 (ja) * 1989-07-14 1999-08-09 雪印乳業株式会社 ビフィズス菌を含有する醗酵乳の製造方法
DE4033996A1 (de) * 1990-10-25 1992-04-30 Karl Heinz Hoelzel Enzymatisches stoffwechselprodukt zur symbioselenkung und verfahren zu seiner herstellung
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
EP0768375B2 (fr) * 1992-07-06 2002-06-12 Societe Des Produits Nestle S.A. Bactérie lactique
RU2048517C1 (ru) * 1992-09-24 1995-11-20 Институт микробиологии Штамм бактерий bifidobacterium longum, используемый для приготовления бактериальных препаратов и кисломолочных продуктов
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
RU2031586C1 (ru) * 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения
JPH0782158A (ja) * 1993-09-16 1995-03-28 Yakult Honsha Co Ltd 抗腫瘍剤
JP3623977B2 (ja) * 1993-10-29 2005-02-23 明治乳業株式会社 潰瘍性大腸炎治療剤
JPH07265064A (ja) * 1993-11-23 1995-10-17 Taketoshi Yamada 腸内細菌叢改善組成物
EP0727216B1 (en) * 1994-07-15 2003-05-28 TAIYO KAGAKU Co., LTD. Medicinal composition containing sialic acid derivative
JP2780154B2 (ja) * 1995-02-17 1998-07-30 株式会社ヤクルト本社 ヨーグルト
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
RU2091075C1 (ru) * 1995-06-28 1997-09-27 Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Комплексный бактериальный препарат для лечения и профилактики желудочно-кишечных заболеваний животных
JPH09241179A (ja) * 1996-03-01 1997-09-16 Meiji Seika Kaisha Ltd ビフィドバクテリウム属菌由来の水溶性免疫賦活物質およびその精製法
JP4021951B2 (ja) * 1996-03-01 2007-12-12 わかもと製薬株式会社 乳酸菌を有効成分とする抗胃炎剤、抗潰瘍剤および醗酵食品
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
TW357191B (en) * 1996-06-04 1999-05-01 Food Industry Development Res Institute Bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method the invention relates to bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method
IT1288119B1 (it) * 1996-06-28 1998-09-10 Renata Maria Anna Ve Cavaliere Composizioni dietetiche da utilizzare nell'alimentazione per via enterica
ES2360341T3 (es) * 1997-02-11 2011-06-03 Enterprise Ireland (Trading As Bioresearch Ireland) Cepas probióticas de lactobacillus salivarius y agentes antimicrobianos obtenidos a partir de las mismas.
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
RU2109054C1 (ru) 1997-04-01 1998-04-20 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Консорциум бифидобактерий bifidobacterium bifidum 791, b. longum b 379 m, b. breve 79-119, b. infantis 73-15, b. adolescentis г 7513 для приготовления кисломолочных, неферментированных пищевых продуктов и бактерийных препаратов
CN1178703A (zh) * 1997-08-06 1998-04-15 北京东方百信生物技术有限公司 幼儿胃肠安制剂及其生产工艺
EP0904784A1 (en) 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
US5902743A (en) * 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
FI980782L (fi) 1998-04-03 1999-10-04 Timo Korhonen Epiteelisoluihin sitoutuva proteiinialue ja sitä koodaava DNA-sekvenssi
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
AU4161199A (en) 1998-05-29 1999-12-20 Enterprise Ireland Trading As Bioresearch Ireland Process for the manufacture of probiotic cheese
AU770726B2 (en) * 1998-10-20 2004-02-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
AUPQ415899A0 (en) 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
JP3944076B2 (ja) 2000-08-25 2007-07-11 わかもと製薬株式会社 乳酸菌含有プロバイオティクス製品
US6618973B2 (en) * 2001-05-15 2003-09-16 Ned H. Nelson Banner holder

Also Published As

Publication number Publication date
EP1688481A1 (en) 2006-08-09
IL144185A (en) 2009-05-04
CN101744841A (zh) 2010-06-23
NO20013429L (no) 2001-08-27
WO2000042168A3 (en) 2000-11-16
US20060292133A1 (en) 2006-12-28
AU3071700A (en) 2000-08-01
CN100552016C (zh) 2009-10-21
US20050214272A1 (en) 2005-09-29
RU2279282C2 (ru) 2006-07-10
JP4706016B2 (ja) 2011-06-22
JP2002534113A (ja) 2002-10-15
IL144184A0 (en) 2002-05-23
US20050084482A1 (en) 2005-04-21
DE60035670D1 (de) 2007-09-06
IE20000033A1 (en) 2000-08-09
US20020006432A1 (en) 2002-01-17
CN101744841B (zh) 2013-05-15
DK1143985T3 (da) 2007-11-19
PT1141235E (pt) 2006-10-31
US20080311080A1 (en) 2008-12-18
ID30449A (id) 2001-12-06
DE60028003D1 (de) 2006-06-22
RU2001119046A (ru) 2003-06-20
DE60035670T2 (de) 2008-04-30
EP1143985A2 (en) 2001-10-17
NZ529353A (en) 2005-06-24
CA2724287A1 (en) 2000-07-20
EP1143985B1 (en) 2007-07-25
WO2000042429A3 (en) 2001-10-11
NZ530273A (en) 2005-04-29
CN1342196A (zh) 2002-03-27
NO20013467L (no) 2001-09-14
CA2360243A1 (en) 2000-07-20
WO2000041707A3 (en) 2001-09-27
CN1245994C (zh) 2006-03-22
BR0007550A (pt) 2001-10-30
EP1141235B1 (en) 2006-05-17
BRPI0007481B8 (pt) 2021-07-06
CA2359334C (en) 2011-03-22
US20030215467A1 (en) 2003-11-20
DE60028003T2 (de) 2007-04-12
US7195906B2 (en) 2007-03-27
WO2000042168A2 (en) 2000-07-20
CN1338940A (zh) 2002-03-06
HK1044964B (zh) 2010-01-15
MXPA01007152A (es) 2003-04-02
TR200102058T2 (tr) 2001-12-21
EP1143985A3 (en) 2002-08-28
EP1145001B1 (en) 2006-05-10
DK1141235T3 (da) 2006-09-18
CA2359334A1 (en) 2000-07-20
TR200102059T2 (tr) 2002-02-21
NO20013467D0 (no) 2001-07-12
US20080057109A1 (en) 2008-03-06
US20060002908A1 (en) 2006-01-05
ATE326525T1 (de) 2006-06-15
ATE326012T1 (de) 2006-06-15
WO2000041707A2 (en) 2000-07-20
RU2308483C2 (ru) 2007-10-20
US20070141039A1 (en) 2007-06-21
WO2000042429A2 (en) 2000-07-20
US20030166257A1 (en) 2003-09-04
US20030170217A1 (en) 2003-09-11
DE60027866D1 (de) 2006-06-14
US20050074441A1 (en) 2005-04-07
AU3071600A (en) 2000-08-01
JP2004502633A (ja) 2004-01-29
NO20013429D0 (no) 2001-07-10
BRPI0007481B1 (pt) 2015-12-15
US20100112003A1 (en) 2010-05-06
ES2265331T3 (es) 2007-02-16
AU779405B2 (en) 2005-01-20
IL144185A0 (en) 2002-05-23
NO327792B1 (no) 2009-09-28
AU3071500A (en) 2000-08-01
HK1044964A1 (zh) 2002-11-08
ID29150A (id) 2001-08-02
EP1145001A2 (en) 2001-10-17
ES2290008T3 (es) 2008-02-16
EP1141235A2 (en) 2001-10-10
MXPA01007144A (es) 2002-04-24
ATE367820T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
BRPI0007481A (pt) formulação contendo cepa de bifidobacterium e uso da mesma
IL245955B (en) Immunogenic compositions for the prevention and treatment of meningococcal disease
BR0211438A (pt) Cepas de lactobacillus casei próbióticas
NO20022974D0 (no) Anvendelse av biologisk aktive vitamin D-forbindelser for forhindring og behandling av inflammatorisk tarmsykdom
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
ATE491436T1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
EE04854B1 (et) Oksabispidiinühendid, nende valmistamise meetod ning ravimvorm kasutamiseks südame arütmia raviks ja profülaktikaks
DE69802260D1 (de) Pharmazeutische Zusammensetzungen enthaltend Lactobacillus brevis und Lactobacillus salivarius zur Behandlung von Vaginainfektionen
CA2408537A1 (en) Treating irritable bowel syndrome or disease
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
NO20014314L (no) Blandinger og metoder for behandling av stafylokokkisk infeksjon
EE200200305A (et) Südame arütmiate ravis kasutatavad uued asabitsüklooktaani derivaadid
WO2000058475A3 (en) Streptococcus pneumoniae antigens
TR199802270A2 (xx) S�lfonamid-ikame etmi� anelize 5-halka-bile�ikleri.
EE200300495A (et) 3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
TR199800597T1 (xx) Papillum ait deri iltihab� tedavisi ve �nlenmesi.
EE200300506A (et) 3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
EP1141295A4 (en) MUTANTS OF HUMAN CHEMOKIN BETA-10 POLYPEPTIDES
ITRM20000351A0 (it) Preparato e suo procedimento di preparazione per la prevenzione e/o la cura della caduta di capelli.
ITMI20001316A0 (it) Composizioni farmaceutiche e/o dietetiche dotate di attiviata' antiossidante e antiglicosilante e contenenti ceppi di lactobacilli eubiotici

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/12/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/01/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 23A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2705 DE 08/11/2022 POR TER SIDO INDEVIDA.